Floatz logo

Biodfence G3

Erectile Dysfunction Following Radical Prostatectomy

AdventHealthPhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Erectile Dysfunction Following Radical Prostatectomy cohort.

Asset / SponsorPhaseRating
Tadalafil
Surgical Outcomes Research Centre (SOuRCe)
Phase 4BB
Sildenafil
The Netherlands Cancer Institute
Phase 4BB
Ningmitai
Xintian Pharmaceutical
Phase 4BB
Indocyanine Green
Ankara University
Phase 4BB
BAY38-9456
Bayer
Phase 4BB

View all 38 →

Same molecule, other indications

Biodfence G3 is also rated in:

prostate cancerDormant
B
Indicative ·
57 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Incontinence, UrinaryDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →